# SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease

> **NCT05765110** · NA · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 80 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **OTHER:** Dopaminergic OFF drug state
- **OTHER:** DBS OFF state
- **OTHER:** Dopaminergic ON drug state
- **OTHER:** DBS ON state

## Key facts

- **NCT ID:** NCT05765110
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-03
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765110, "SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05765110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*